Michel Delforge

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi, Larry D. Anderson, Nina Shah et al. · New England Journal of Medicine · 2021 · 2.4K citations · Full text

Medicine, Hematology, Oncology +17

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 953 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

Meletios Α. Dimopoulos, Philippe Moreau, Evangelos Terpos et al. · Annals of Oncology · 2021 · 820 citations · Full text

Medicine, Hematology, Oncology +14

Neutrophil extracellular trap cell death requires both autophagy and superoxide generation

Quinten Remijsen, Tom Vanden Berghe, Ellen Wirawan et al. · Cell Research · 2010 · 806 citations · Full text

Life Sciences, Cell Biology, Immunology +17

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Jesús F. San Miguel, Katja Weisel, Philippe Moreau et al. · The Lancet Oncology · 2013 · 799 citations · Full text

Medicine, Oncology, Pharmacotherapy +12